Commentary

Leukemia Research

Volumn 38, Issue 9, 2014, Pages 1013-1015

  Gale, Robert Peter ^a   Barosi, Giovanni ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB;

CANCER INHIBITION; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; HIGH RISK POPULATION; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

HUMANS; PRIMARY MYELOFIBROSIS;

EID: 84906940696     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.06.012     Document Type: Editorial

References (12)

1. Savona M.R. Are we altering the natural history of primary myelofibrosis?. Leuk Res 2014, 38:1004-1012.
2. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
3. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
4. Wade R., Rose M., Neilson A.R., Stirk L., Rodriguez-Lopez R., Bowen D., et al. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. Pharmacoeconomics 2013, 31:841-852.
5. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008, 336:924-926.
6. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98:1865-1871.
7. Cervantes F., Vannucchi A.M., Kiladjian J.J., Al-Ali H.K., Sirulnik A., Stalbovskaya V., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013, 122:4047-4053.
8. Hernán M.A., Hernández-Díaz S., Robins J.M. Randomized trials analyzed as observational studies. Ann Intern Med 2013, 159:560-562.
9. Li J., Kent D.G., Godfrey A.L., Manning H., Nangalia J., Aziz A., et al. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood 2014, 123:3139-3151.
10. Mullally A., Lane S.W., Ball B., Megerdichian C., Okabe R., Al-Shahrour F., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
11. Koppikar P., Abdel-Wahab O., Hedvat C., Marubayashi S., Patel J., Goel A., et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010, 115:2919-2927.
12. Girardot M., Pecquet C., Chachoua I., Van Hees J., Guibert S., Ferrant A., et al. Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene 2014, [Epub ahead of print]. 10.1038/onc.2014.60.